BioSpace News Archive

Genedata today announced that Debiopharm, a Swiss-based, global biopharmaceutical company is adopting Genedata Profiler® as its single point of access to translational research data to accelerate its R&D activities and bring life-saving drugs faster to underserved patients.

During the conference on 23 May, French MedTech Biosency unveiled its latest clinical results demonstrating the ability of its BVS3 technology to predict acute COPD (chronic obstructive pulmonary disease) exacerbations on average 3 days prior to hospitalisation in 86% of cases, with only 9% false positives.

Synapse Medicine, the leader in medication success, and CompuGroup Medical, the leader in software for providers, have announced a partnership to accelerate innovation in prescribing and allow physicians to benefit from time-saving technological advances in clinical decision support.

GE HealthCare, a leading medical technology innovator, announced its largest ever CT deal in the United States – a $30 million order by St. Luke’s University Health Network, a nationally recognized nonprofit healthcare network, to install 21 of GE HealthCare’s innovative CT systems, powered by Artificial Intelligence, across their system.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer, has enrolled 134 patients, representing more than 50% of the total planned enrollment for the study.

Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week.

ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Frontiers in Medicine, demonstrating a role for innate inflammasome activation in two of the most common types of JIA, oligo- and poly-articular, both of which are typically thought to be classical antigen-driven autoimmune conditions.

Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s intellectual property portfolio made important advancements in Europe.

Therapeutic Solutions International (TSOI) announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell adult stem cell platform for treatment of chronic traumatic encephalopathy.

Indivior PLC announced that it will participate in the following investor events: